Individual risk assessment for intracranial haemorrhage during thrombolytic therapy

[1]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[2]  F. Van de Werf,et al.  The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. , 1992, The New England journal of medicine.

[3]  C. Kase,et al.  Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. , 1992, The American journal of medicine.

[4]  L. R. Caplan,et al.  Intracerebral haemorrhage , 1992, The Lancet.

[5]  R. Califf,et al.  Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group. , 1992, Journal of the American College of Cardiology.

[6]  Ruth Bonita,et al.  Epidemiology of stroke , 1992, The Lancet.

[7]  M. Marmot,et al.  Primary prevention of stroke , 1992, The Lancet.

[8]  M. Simoons,et al.  Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors. , 1992, Journal of the American College of Cardiology.

[9]  J. Gore,et al.  Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. , 1991, Circulation.

[10]  C McRae,et al.  Myocardial infarction. , 2019, Australian family physician.

[11]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.

[12]  J. Tijssen,et al.  Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands. , 1989, Journal of the American College of Cardiology.

[13]  U. Tebbe,et al.  Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. , 1989, Journal of the American College of Cardiology.

[14]  K. Lee,et al.  A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. , 1989, Circulation.

[15]  J. Tijssen,et al.  Long term benefit of early thrombolytic therapy in patients with acute myocardial infarction , 1989 .

[16]  F. Van de Werf,et al.  Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. , 1988, BMJ.

[17]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[18]  R. Califf,et al.  Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. , 1988, The American journal of medicine.

[19]  L. Bolognese,et al.  RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.

[20]  Dwight E. Peake,et al.  Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .

[21]  R. Califf,et al.  Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. , 1988, Circulation.

[22]  M. Simoons,et al.  Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase. Twelve month follow up report of the randomised multicentre trial conducted by the Interuniversity Cardiology Institute of The Netherlands. , 1988, British heart journal.

[23]  H. Lambertz,et al.  THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTY , 1988, The Lancet.

[24]  B. Chaitman,et al.  The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. , 1987, Journal of the American College of Cardiology.

[25]  E. Braunwald,et al.  Update from the Thrombolysis in Myocardial Infarction Trial. , 1987, Journal of the American College of Cardiology.

[26]  K. Lee,et al.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.

[27]  S. Forman,et al.  Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. , 1987, Journal of the American College of Cardiology.

[28]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[29]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .

[30]  P. Serruys,et al.  Which patients benefit most from early thrombolytic therapy with intracoronary streptokinase? , 1986, Circulation.

[31]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[32]  R. W. Brower,et al.  RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator , 1985, The Lancet.

[33]  B. Schulte,et al.  Epidemiology of stroke in Tilburg, the Netherlands. The population‐based stroke incidence register: 2. Incidence, initial clinical picture and medical care, and three‐week case fatality. , 1982, Stroke.

[34]  J. G. Evans,et al.  The epidemiology of stroke. , 1979, Age and ageing.